SRR23036891
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.550
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.500
- TNFA_SIGNALING_VIA_NFKB+0.380
- MYC_TARGETS_V2+0.340
- ALLOGRAFT_REJECTION+0.300
- E2F_TARGETS+0.300
- KRAS_SIGNALING_UP+0.300
- TGF_BETA_SIGNALING+0.270
- MYC_TARGETS_V1+0.260
- INFLAMMATORY_RESPONSE+0.230
Top 10 suppressed
- CHOLESTEROL_HOMEOSTASIS-0.270
- FATTY_ACID_METABOLISM-0.240
- ESTROGEN_RESPONSE_EARLY-0.220
- OXIDATIVE_PHOSPHORYLATION-0.170
- PEROXISOME-0.170
- PI3K_AKT_MTOR_SIGNALING-0.160
- ESTROGEN_RESPONSE_LATE-0.150
- ANDROGEN_RESPONSE-0.140
- PROTEIN_SECRETION-0.140
- BILE_ACID_METABOLISM-0.130
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | AUR-AE5H-TTP1-A-1-1-R-A742-41 | — | D | 0.858 |
| 2 | ERR2278875 | — | — | 0.809 |
| 3 | X55db60cd.e752.41b4.aa3e.f68d676031f7 | — | cohortA1 | 0.796 |
| 4 | 2dbf638a-46c1-4ec8-b81d-d859c7dcf989 | — | — | 0.793 |
| 5 | TCGA-FD-A3B7-01A-31R-A20F-07 | — | — | 0.792 |
| 6 | 333376 | EPN | Supratentorial EPN | 0.789 |
| 7 | TCGA-CQ-A4CB-01A-11R-A24Z-07 | — | — | 0.783 |
| 8 | TCGA-GC-A3YS-01A-11R-A23N-07 | — | — | 0.780 |
| 9 | R385 | — | — | 0.780 |
| 10 | SRR8943028 | — | — | 0.778 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.550 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.500 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.380 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.340 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.300 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.270 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.260 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.230 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.220 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.200 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.190 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.190 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.170 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.150 | Cobimetinib | — uncovered |
| COAGULATION | 0.120 | Binimetinib | — uncovered |
| COMPLEMENT | 0.120 | Inavolisib | — uncovered |